3 COLUMBUS CIRCLE, NEW YORK, NY
Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Indaptus Therapeutics Enters $12M Stock Purchase Agreement
Director Resignations - David E. Lazar and Avraham Ben-Tzvi Step Down
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Amended material disclosure
Board Appointment - Tim Ruan and Yi Zhang Join Indaptus Therapeutics Board
CFO Resignation; Nir Sassi Steps Down, Qinglai Lu Appointed Director
Changes in Control; David E. Lazar Acquires Preferred Stock
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Amended Registration Statement for Securities
Prospectus filed pursuant to Rule 424(b)(5)
S-1
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Schedule 13D - Ownership Report
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement